Evaluating Oncologists’ Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma: The US Physician PARADIGM Study
The Oncologist · 04.03.2024 · 29 (3) · 244-253
DOI: 10.1093/oncolo/oyad267 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 16.10.2023. Verfasst von Shilpa Gupta und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Oncologists, Physicians. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: EMD Serono, Inc., Rockland, MA, USA.
Abstract (Originalsprache)
Background
The treatment landscape for locally advanced/metastatic urothelial carcinoma (la/mUC) has evolved. This study examined US prescribing patterns and clinical decision-making for first-line (1L) and first-line maintenance (1LM) treatment. Materials and Methods US-based oncologists (N = 150) completed an online survey on patient demographics, practice patterns, and important factors considered in 1L/1LM selection. Multivariable logistic regression was used to assess factors associated with more vs less frequent 1L/1LM prescribing.
Results
Physician reports estimated that 23% of patients with la/mUC had not received any systemic therapy in the previous 6 months; however, 46% received 1L, 32% received second-line, and 22% received subsequent-line systemic treatments. Of patients who were receiving 1L treatment, 72% were estimated to be receiving 1L platinum-based chemotherapy. Around 69% of patients eligible for 1LM received the treatment. Physicians categorized as frequent prescribers reported overall survival (OS), disease control rate (DCR), and rate of grade 3/4 adverse events (AEs) as factors associated with 1L treatment selection (all P < .05). OS, rate of grade 3/4 immune-mediated AEs, and inclusion in institutional guidelines were reported as attributes used in 1LM treatment selection (all P < .05). Multivariable analysis revealed OS, DCR, and rate of grade 3/4 AEs as important factors in oncologists’ 1L treatment selection; academic practice setting and use of Response Evaluation Criteria in Solid Tumors version 1.1 were associated with 1LM use (all P < .05).
Conclusion
OS and AEs were found to be relevant factors associated with offering 1L and 1LM treatment. Variability exists in physicians’ decision-making in the real-world setting for la/mUC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
- Cerner Enviza, an Oracle company, Kansas City, MO, USA.
- EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA.
- Pfizer, New York, NY, USA.
Förderung
- EMD Serono, Inc., Rockland, MA, USA
Zitieren
APA
Gupta, S., Costantino, H., Ike, C., Gupta, S., Bhanegaonkar, A., Su, C., Thakkar, S., Mackie, D. S., Devgan, G., Katzenstein, H. M., & Liu, F. X. (2024). Evaluating Oncologists’ Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma: The US Physician PARADIGM Study. The Oncologist, 29(3), 244-253. https://doi.org/10.1093/oncolo/oyad267
Vancouver
Gupta S, Costantino H, Ike C, Gupta S, Bhanegaonkar A, Su C, et al. Evaluating Oncologists’ Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma: The US Physician PARADIGM Study. The Oncologist. 2024;29(3):244-253. doi:10.1093/oncolo/oyad267
BibTeX
@article{Gupta2024,
author = {Gupta, Shilpa and Costantino, Halley and Ike, Chiemeka and Gupta, Shaloo and Bhanegaonkar, Abhijeet and Su, Cathy and Thakkar, Sheena and Mackie, deMauri S and Devgan, Geeta and Katzenstein, Howard M and Liu, Frank X},
title = {Evaluating Oncologists’ Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma: The US Physician PARADIGM Study},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {3},
pages = {244--253},
doi = {10.1093/oncolo/oyad267}
}
EUVIMED